- Home
- OSS vs LCTX Comparison
OSS vs LCTX Comparison
Compare OSS & LCTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | OSS | LCTX |
|---|---|---|
| Founded | 1998 | 1990 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Manufacturing | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 309.4M | 301.7M |
| IPO Year | 2017 | 1996 |
Fundamental Metrics
Financial Performance| Metric | OSS | LCTX |
|---|---|---|
| Price | $13.30 | $1.11 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 4 |
| Target Price | ★ $10.00 | $6.25 |
| AVG Volume (30 Days) | ★ 1.1M | 959.1K |
| Earning Date | 05-06-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 133.85 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,027,382.00 | $14,556,000.00 |
| Revenue This Year | $22.19 | $109.40 |
| Revenue Next Year | $20.67 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 34.46 | ★ 53.24 |
| 52 Week Low | $4.17 | $0.97 |
| 52 Week High | $20.88 | $2.09 |
Technical Indicators
Market Signals| Indicator | OSS | LCTX |
|---|---|---|
| Relative Strength Index (RSI) | 48.58 | 46.48 |
| Support Level | $7.45 | $1.00 |
| Resistance Level | $14.10 | $1.32 |
| Average True Range (ATR) | 1.23 | 0.06 |
| MACD | 0.24 | 0.01 |
| Stochastic Oscillator | 66.97 | 72.22 |
Price Performance
Historical ComparisonAbout OSS One Stop Systems Inc.
One Stop Systems Inc designs, manufactures, and markets specialized rugged high-performance compute ("HPC"), high-speed switch fabrics, and storage systems, which are designed to target edge applications for artificial intelligence ("AI") / machine learning ("ML"), sensor processing, sensor fusion, and autonomy.
About LCTX Lineage Cell Therapeutics Inc.
Lineage Cell Therapeutics Inc is a clinical-stage biotechnology company focused on the development and commercialization of novel therapies for the treatment of degenerative diseases. The company's pipeline currently includes: OpRegen, OPC1, ReSonance, ILT1, RND1, PNC1, and LCT-CON. Its programs are based on its proprietary, in-house, cell-based manufacturing platform, which it call AlloSCOPE (Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering), and supported by its associated development, formulation, manufacturing, and delivery capabilities. The AlloSCOPE platform is a proprietary differentiation and production modality from which, a single, well-characterized pluripotent cell line can create a stable current Good Manufacturing Practice, master cell bank.